- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma Secures Interim Court Relief In URSOCOL Trademark Dispute

New Delhi: In a relief to Sun Pharma Laboratories Limited, the Bombay High Court has granted an interim injunction restraining Rambos Lifesciences Pvt. Ltd. from using the trademarks URSOCAL and URSOCAL-300, observing that they infringe upon Sun Pharma's registered liver drug trademark URSOCOL.
The dispute revolves around Sun Pharma’s allegation that Rambos Lifesciences adopted and marketed pharmaceutical products under the marks URSOCAL and URSOCAL-300, which are “deceptively similar” to its well-established brand URSOCOL. Sun Pharma argued that such similarity was likely to create confusion among doctors, chemists, and patients in the sensitive pharmaceutical sector.
Hearing the matter, Justice Arif S Doctor, through an order dated 20 August 2025, categorically restrained Rambos and its associates from infringing Sun Pharma’s rights. The Court observed that confusion in medicinal products could have serious consequences and therefore warranted urgent protection.
The Court held:
“That pending the hearing and final disposal of the suit, the Respondents … be restrained by a temporary order and injunction of this Hon'ble Court from infringing the Applicant's registered trade mark 'URSOCOL' bearing registration no.1119429 in class 5, by the use of the impugned trade mark 'URSOCAL' and/or 'URSOCAL-300' and/or any other trademark containing the word 'URSOCAL' and/or any other trade mark identical with and/or deceptively similar to the Applicant's said registered trade mark.”
Earlier, on 16 July 2025, the Court had appointed the Court Receiver with wide powers to take possession of infringing goods, packaging materials, and related documents from the Respondents.
The order stated,
"That pending the hearing and final disposal of the suit, the Respondents by themselves, through their promotors, proprietors, Meera Jadhav 3/3 17-iaL-20229-25.doc partners, directors, affiliates, associate/s, sister/group companies, employees, manufacturers, servants, agents, stockists, super- stockiest, e-commerce and warehouse aggregators, distributors, purchasers, dealers, franchisees, licensees, assigns, wholesalers, retailers, custodians, importers, exporters, predecessors, successors and all persons claiming through and/or under them or acting on their behalf or connected with them in their business be restrained by a temporary order and injunction of this Hon'ble Court from infringing the Applicant's said registered trade mark 'URSOCOL' bearing registration no.1119429 in class 5, by the use of the impugned trade mark 'URSOCAL' and/or 'URSOCAL-300'and/or any other trademark containing the word 'URSOCAL' and/or any other trade mark identical with and/or deceptively similar to the Applicant's said registered trade mark bearing no.1119429 in class 5 in respect of the goods covered by the Applicant's said registration or like goods or in any other manner whatsoever."
This order was executed on 6 August 2025, and the Court Receiver filed Report No. 371 of 2025 outlining the steps taken.
Recording this, the Court adjourned the matter to 29 August 2025, as service on Defendant No.1 was noted to be incomplete.
The matter remains sub judice, and the interim relief continues to operate until final adjudication
To view the official order, click the link below:
Mpharm (Pharmacology)
Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.